Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
114.00    2.50 (2.24%)
Bid:
112.00
Ask:
116.00
Spread: 4.00 (3.571%)
Market Cap: £68.59m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Trading Update

7 Oct 2009 07:00

RNS Number : 3501A
Intercede Group PLC
07 October 2009
 



7 OCTOBER 2009

INTERCEDE GROUP plc

("Intercede" or "the Company")

Trading Update

Intercede, a leading producer of Identity and Credential Management Systems (IDCMS) software, today announces excellent progress in the six months ended 30 September 2009.

Sales for the first half of the current financial year are more than 40% higher than for the comparable period last year. The Directors are also pleased to report that the Company has strongly increased its operating profit before exceptional items during the period.

The growth in sales is especially encouraging, because it is based both on existing customers expanding deployments installed in earlier periods and on new licence sales into new markets for actual end-customer projects. As a result, we are now experiencing a return on the investment made in development and sales efforts in previous years. Our expansion into new sectors and territories is also producing a fresh and immediate stream of revenue. This is evidence of the ongoing strength and viability of Intercede's business model and of a strategy that is being successfully executed. 

Key achievements during the period include:

Maintaining and expanding existing major projects for Lockheed MartinUK Government, US Federal Government, NHS and others. 

Winning new contracts to supply MyID to customers in AustraliaAustriaCzech RepublicRomaniaSlovakiaSwitzerland and the US.

Deploying MyID systems at a major security printing and smart card manufacturer, at a major Scandinavian bank and within a European government agency.

Adding the US Social Security Administration to Intercede's Federal HSPD-12 customer list. 

Further details will be provided when Intercede announces its Interim Results for the six months ended 30 September 2009, which is expected to take place in December 2009.

The reported period includes exceptional costs for defending a previously reported patent infringement case in the US filed by ActivIdentity Corporation. Intercede's answer and counterclaims deny that its products infringe ActivIdentity's patent and allege further that this patent is invalid and unenforceable. In addition, Intercede has filed counterclaims against ActivIdentity, including alleging violations of US antitrust law. The court recently rejected ActivIdentity's challenge to Intercede's antitrust claims and one basis for a declaration of unenforceability. While the court dismissed other counterclaims alleging fraudunfair competition, and an additional basis for a declaration of unenforceability, it gave Intercede the right to re-plead those claims with more factual detail. Intercede filed its amended counterclaims on 28 September 2009. Intercede intends to pursue its defence and its counterclaims vigorously. 

Costs and cash collections have also been kept under control throughout the period, as evidenced by a half year cash balance of £3,913,00, compared to £3,711,000 at 31 March 2009 and £1,839,000 at 30 September 2008. The cash position as at 30 September 2009 is thus more than double that of a year ago, notwithstanding the legal costs incurred to date in defending the patent infringement case brought by ActivIdentity and in pursuing the Company's counterclaims against ActivIdentity. 

Richard ParrisIntercede's Chairman and Chief Executive, said:

"Our order book indicates that Intercede is on track to continue our planned growth trajectory for this year and beyond. I am delighted that our sales pipeline is stronger than ever and that a number of our existing larger projects are set to exceed expectations in terms of future growth. In particular our entry into the national identity market is proving to be particularly rewarding while our partnerships with Lockheed Martin, Thales and VeriSign are making continuing and growing contributions to operating profit."

About Intercede 

Intercede is the producer of the MyID® Identity and Credential Management System (IDCMS). Intercede's MyID is the only IDCMS software product that enables organizations to easily and securely manage the identities of people and their associated identity credentials within a single, integrated, workflow driven platform. This includes enabling and managing: secure registration, biometric capture, application vetting and approval through to smart card personalization, issuance and management. Intercede's MyID is being used around the world by large corporations, governments and banks to manage millions of identities for employees, citizens and customers. Notable deployments in the US include 10 Federal Agencies, a programme with Lockheed Martin and two major US financial institutions. In Europe and the Middle East, Intercede's MyID is being deployed in support of government identity, health and corporate employee ID security projects.

Intercede and MyID are registered trademarks or trademarks in the UK, US and/or other countries. 

For more information visit http://www.intercede.com.

ENQUIRIES

Intercede Group plc

Tel. +44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

FinnCap

Charles Cunningham

Tel. +44 (0)20 7600 1658

Pelham Public Relations

Archie Berens

Tel. +44 (0)20 7337 1509

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRFSMFMMSUSEFS
Date   Source Headline
20th May 20267:00 amRNS-RPartnership with OneSpan
19th May 20267:00 amRNSNotice of Results and Investor Presentation
11th May 20262:50 pmRNSShare Incentive Scheme
21st Apr 20267:00 amRNSNew Contract Upsell Orders and Renewal
9th Apr 20267:00 amRNSTrading Update, Renewals and New Contract Orders
17th Mar 20267:00 amRNSYear End Trading Update
17th Mar 20267:00 amRNSYear End Trading Update
9th Feb 202612:55 pmRNSHolding(s) in Company
15th Jan 202610:44 amRNSExercise of Options & Total Voting Rights
24th Dec 20257:00 amRNSExercise of Options & Total Voting Rights
2nd Dec 20251:05 pmRNSHolding(s) in Company
25th Nov 20257:01 amRNSNew Contract Awards and Renewals
25th Nov 20257:00 amRNSHalf-year Report
22nd Oct 20252:15 pmRNSNotice of Interim Results & Investor Presentation
13th Oct 20257:00 amRNSExercise of Options, PDMR Shareholding & TVR
10th Oct 202510:25 amRNSDirector/PDMR Shareholding
9th Oct 20251:02 pmRNSDirector/PDMR Shareholding
9th Oct 20257:00 amRNSTrading Update, New Contract awards and Renewals
25th Sep 20251:03 pmRNSResult of AGM
22nd Sep 20257:00 amRNSNon-Executive Director Change
22nd Aug 20257:00 amRNSIssue of Equity & Total Voting Rights
12th Aug 20257:00 amRNSNotice of AGM and release of Annual Report 2025
24th Jul 20257:00 amRNS-RFirst CMS to support FIDO enterprise attestation
22nd Jul 20257:00 amRNSGrowth Share Scheme Vesting and Award Allocation
3rd Jul 20257:00 amRNSNew Contract Orders and Renewals
25th Jun 20256:01 pmRNSDirector/PDMR Shareholding
25th Jun 20257:00 amRNSDirector/PDMR Shareholding
24th Jun 20257:00 amRNSFinal Results
22nd May 20253:14 pmRNSNotice of Results & Investor Presentation
7th May 20257:00 amRNSShare Incentive Scheme
1st May 20257:00 amRNS-RIntercede Collaborates with Microsoft and Yubico
8th Apr 20257:00 amRNSTrading Update
2nd Apr 20257:00 amRNSMomentum maintained with New Contract Orders
31st Mar 202511:48 amRNSHolding(s) in Company
12th Mar 20251:54 pmRNSDirector/PDMR Shareholding
12th Mar 20257:00 amRNSContinued Momentum with New Contract Orders
8th Jan 20257:00 amRNSContract Orders and Renewals
24th Dec 20247:00 amRNSTransaction in Own Shares
23rd Dec 20247:00 amRNSTransaction in Own Shares
19th Dec 20247:00 amRNSTransaction in Own Shares
13th Dec 20247:00 amRNSTransaction in Own Shares
11th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
5th Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20247:00 amRNSTransaction in Own Shares
29th Nov 20247:00 amRNSTransaction in Own Shares
28th Nov 20247:00 amRNSTransaction in Own Shares
27th Nov 20247:00 amRNSTransaction in Own Shares
26th Nov 20247:00 amRNSTransaction in Own Shares
26th Nov 20247:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.